Articles

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite, France;French CML Group (Fi-LMC group), Poitiers, France
Centre for Haematology, Imperial College London, London, UK
Molecular Biology Unit, University of Bologna, Bologna, Italy
Molecular Biology Unit, University of Bologna, Bologna, Italy
III. Medizinische Klinik, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany
Universitätsklinikum Jena, Jena, Germany
Department of Hematology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
Department of Hematology, St Mary's Hospital, The Catholic University of Korea, Seoul, Korea
Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Oregon Health & Science University, Knight Cancer Institute, Center for Hematologic Malignancies, Portland, OR, USA
Department of Hematology, Singapore General Hospital; Cancer & Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore
Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite, France
Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite, France
Laboratoire de Cytogénétique, Hôpital Jeanne de Flandre, Lille, France;French CML Group (Fi-LMC group), Poitiers, France
Laboratoire de Cytogénétique et de Biologie Moléculaire, Hôpital Haut Lévêque, Pessac, France
Laboratory for Hematology and UMR5239, Centre Hospitalier Lyon Sud, Pierre Bénite, France;French CML Group (Fi-LMC group), Poitiers, France
Merck Research Laboratories, North Wales, PA, USA
Merck Research Laboratories, North Wales, PA, USA
Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Lyon, France;French CML Group (Fi-LMC group), Poitiers, France
Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite, France;French CML Group (Fi-LMC group), Poitiers, France
Centre for Haematology, Imperial College London, London, UK
Centre for Haematology, Imperial College London, London, UK
Laboratoire de Cytogénétique et de Biologie Moléculaire, Hôpital Haut Lévêque, Pessac, France;Institut Bergonié, Bordeaux, France;French CML Group (Fi-LMC group), Poitiers, France
Centre for Haematology, Imperial College London, London, UK
Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Lyon, France;French CML Group (Fi-LMC group), Poitiers, France
Vol. 98 No. 10 (2013): October, 2013 https://doi.org/10.3324/haematol.2012.080234